About Vite Stro
Vite Stro is a company based in Utrecht (Netherlands) founded in 2017 by Toon Overbeeke and Brian Joseph. Vite Stro has raised $104.86 million across 6 funding rounds from investors including European Union, EIC Fund and Sonder Capital. Vite Stro offers products and services including Aletta.
- Headquarter Utrecht, Netherlands
- Founders Toon Overbeeke, Brian Joseph
- SectorsHealthcareIndustrial Goods & Manufacturing
- Email••••••••
- Phone•••• ••••
- Website vitestro.com
- Social LinkedIn X
- Total Equity Funding$104.86M (USD)
in 6 rounds
- Latest Funding Round$70M (USD), Series B
Mar 2026
- InvestorsEuropean Union
& 10 more
Products & Services of Vite Stro
Vite Stro offers a comprehensive portfolio of products and services, including Aletta.
Autonomous AI device for precise and safe blood drawing.
Funding Insights of Vite Stro
Vite Stro has successfully raised a total of $104.86M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $70 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $104.86M
- Total Rounds 6
- Last Round Series B — $70M
- First Round $2.65M
(Jan 2020)
- Investors Count 11
All 6 funding rounds of Vite Stro with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $70M | Series B | – | – | |
| Apr 2024 | $22M | Series B | – | Sonder Capital | |
| Mar 2023 | – | Grant | – | – | |
| Mar 2023 | $12.86M | Series A | – | Sonder Capital | – |
| Dec 2021 | $56,620 | Grant | – | – | |
| Jan 2020 | $2.65M | Grant | – | – |
11 investors in total: 11 institutional.
Investors in Vite Stro
Vite Stro has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, EIC Fund and Sonder Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Early stage medtech startups are invested in by Sonder Capital. | – | sondercapital.com | San Carlos, United States | |
Infrastructure and venture capital funding is provided in key sectors. | – | invest-nl.nl | Amsterdam, Netherlands | |
- | – | nybcventures.com | - | |
- | – | pumaventurecapital.com | - | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
- | – | pggm.nl | - | |
- | – | romutrechtregion.nl | - | |
- | – | labcorp.com | - | |
- | – | mayoclinic.org | - |
Investor details for Vite Stro
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vite Stro
28 people are tracked at Vite Stro (9 in leadership, 19 in team).
| Name | Role | Group |
|---|---|---|
Toon Overbeeke | Co-Founder & CEO | Leadership |
Brian Joseph | Co-Founder | Leadership |
Luuk Giesen | Chief Medical Officer | Leadership |
Dewi Hamwijk-Habermehl | Head of People, Culture & Legal | Leadership |
Jim Lelivelt | Chief Financial Officer | Leadership |
Tomas de Boer | Head of Product | Leadership |
Bob Gerberich | Global Chief Commercial Officer | Leadership |
Bert Wiggers | Chief Technology Officer | Leadership |
Colby Wood | Director | Leadership |
Gabriel Zarbiv | Senior QA Officer | Team |
Erdem Hasanoglu | Electrical Engineer | Team |
Marc de Lange | Lead Mechanical Engineer | Team |
Mark van den Broek | Product Strategy | Team |
Tal Korman | Research And Development Engineer | Team |
Jeroen Roest | Sr. Clinical Product Specialist | Team |
Houdijn Beekhuis | Systems Engineer (mechanical Architect) | Team |
Arno Jonker | Npi-lead | Team |
Kemal Cagin Gülsen | Cloud & Security Team Lead | Team |
Olaf de Jager | Legal Counsel | Team |
Jasmine Beukema | Qa/ra Officer | Team |
8 more people are available in the full profile.
Complete people profiles for Vite Stro
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vite Stro
3 dated milestones of Vite Stro across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Vite Stro is founded.
- Funding First funding round of $2.7M.
- Funding Latest funding round, Series B, of $70.0M.
Web traffic of Vite Stro
The website of Vite Stro (vitestro.com) receives about 6.5K visits a month.
- Monthly visits6.5K
▲ 88.2% vs previous month
Latest news on Vite Stro
Complete news archive for Vite Stro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Vite Stro
10 companies that operate in the same segment as Vite Stro (Hematology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small activating RNA therapeutics are developed to restore gene function. | 2008 | London, England, United Kingdom | USD 460.41 M | USD 23.07 M | 37 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 442 M | – | 66 | |
Developer of therapeutics for the treatment of hematologic diseases | 2017 | Cambridge, Massachusetts, United States | USD 140 M | – | 84 | |
Gene therapy platform is developed for chronic disease treatments. | 2015 | Stevenage, Hertfordshire, United Kingdom | USD 273.69 M | USD 435.87 K | 152 | |
Novel anticoagulants for thrombosis treatment are developed. | 2019 | Cambridge, Massachusetts, United States | USD 250 M | – | 14 | |
Developer of therapies for treating hemochromatosis & beta thalassemia | 1989 | San Diego, California, United States | – | USD 75.72 M | 71 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Hematology products and solutions are provided for medical applications. | 1971 | Braintree, Massachusetts, United States | – | USD 1.33 B | 3,020 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Vite Stro
Vite Stro was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Vite Stro is headquartered in Utrecht, Netherlands.
Toon Overbeeke is the current CEO of Vite Stro. They have also founded this company.
Vite Stro is a funded company, having raised a total of $104.86M across 6 funding rounds to date. The company's 1st funding round was a Grant of $2.65M, raised on Jan 2020.
Developed AI-based blood drawing robot for clinic use. The company has developed a medical robotics device that autonomously draws blood from patients. The device has a guided 3D construction with a robotic needle that secures blood collection. It has features for bandage application as well.
Vite Stro offers Aletta.
Vite Stro has 11 investors. Key investors include European Union, EIC Fund, Sonder Capital, Invest-NL, and NYBC Ventures.